The reactions to the decision were mixed. According to
Reuters, the decision could stifle research by
stem cell companies for commercial purposes.[3] In contrast, according to
the Guardian, "some experts believe this will provide a boost for European companies developing technologies based on human embryonic stem cells".[4]
G 1/07 (Treatment by surgery/MEDI-PHYSICS),
G 2/08 (Dosage regime/ABBOTT RESPIRATORY),
G 3/08 (Programs for computers),
G 1/09 (Pending application/SONY),
G 2/10 (Disclaimer/SCRIPPS),
G 1/10 (Request to correct patent/FISHER-ROSEMOUNT),
G 1/11 (Non-refund of further search fees/BAUER),
G 1/12,
G 1/13,
G 2/12 and G 2/13 (Tomatoes II and Broccoli II),
Art. 23 1/15,
Art. 23 2/15,
Art. 23 1/16,
G 1/15 (Partial priority),
G 2/19 (Right to be heard and correct venue for oral proceedings)
2020 – 2029
G 1/19 (Pedestrian simulation),
G 1/21 (Oral proceedings by videoconference)